Eurofarma launches eBulas: artificial intelligence arrives to facilitate access to medication leaflets
The goal is to offer convenience and safety for patients in Brazil.
São Paulo, June 2025 – Eurofarma, a pharmaceutical multinational and a benchmark for innovation in the sector, announces the launch of eBulas, its new virtual assistant powered by artificial intelligence, designed to transform how patients and healthcare professionals access medication information. The solution is already available for Eurofarma and Momenta brand products.
eBulas allows for quick and accurate consultation of leaflets through two channels: web chat and WhatsApp (voice and text). The tool was trained based on official Anvisa leaflets and food and supplement brochures.
In addition to answering questions about dosage, contraindications, and adverse events, eBulas also provides guidance on the correct disposal of medications and offers direct access to the Eurofarma Customer Service Center. The solution will soon be expanded to Mozambique, Angola, and selected Latin American countries.
The initiative is the result of collaboration between the Digital Health - Digital Solutions, Medical Affairs, and Customer Service departments, among others. With eBulas, the company takes another step toward purposeful innovation, promoting accessibility and speed in consulting relevant information for the safe use of medications. The launch of eBulas reinforces Eurofarma's commitment to innovation, patient safety, and the democratization of health information.
How to access:
WhatsApp (voice and text) - currently available only in Portuguese:
Chat (text) - currently available only in Portuguese:
About Eurofarma
Founded in 1972, Eurofarma operates in the healthcare sector, producing and marketing products and services to improve people's quality of life. Focused on shared value generation, it covers key pharmaceutical segments such as prescription drugs, OTC and personal care, generics, hospital, oncology, and animal health, in addition to providing third-party manufacturing services. With broad coverage across therapeutic classes, the portfolio comprises over 4,000 SKUs, serving major medical specialties. A leader in medical prescriptions in Brazil, where it holds the second position in generics, Eurofarma is present in 24 countries, with 100% coverage in Latin America and operations in the USA and Africa. It has 13,300 employees and 11 manufacturing plants, with a total production of 600 million units in 2024. In the same year, it invested over R$ 800 million in innovation projects and achieved a total net revenue of R$ 11 billion.